



Senzime brings together the company's clinical monitoring of glucose and lactate under the same trademark - CliniSenz

Uppsala, Sweden, August 26 2015. Senzime have developed user-friendly products for continuous monitoring of glucose and lactate in complex biological fluids such as blood and cell cultures. These measurements are important – and in many cases critical - for patients undergoing surgeries and whom are at risk for unnecessary and dangerous complications if measurements are not managed correctly. Senzime is now collecting the business' offer for healthcare as one trade mark - CliniSenz.

Senzime's portfolio of measurements for health care has so far been marketed under two brands - CliniSenz (for the ICU) and OneSenz (for primary care and R & D amongst others). In the acquisition of MD Biomedical another brand has been added to the product list - Onzurf Probe - that implements continuous biochemical test samplings in specific organ.

Herein will be the commercialization of Senzime's products in focus, and the company has therefore decided to gather the instruments in accordance with one and only trademark - CliniSenz. Thereby approaching a clarified marketing of the company Senzime towards its partners and users can now be facilitated.

For further information, please contact:

Lena Söderström, CEO Senzime
Tel: +46-708-16 39 12, e-mail: lena.soderstrom@senzime.com

About Senzime

Senzime develops and markets analytical instruments and related disposable products, enabling automated, continuous monitoring of vital substances including glucose (sugar), in biological fluids. Senzime has two platforms for continuously monitoring glucose and lactate – BioSenz in biotech environment and CliniSenz for continuous patient-monitoring. Via microdialysis in tissue or blood Senzime offers a complete system enabling continuous monitoring which is critical to detect post-surgery complications. The company's share is listed on Aktietorget since 2008. www.senzime.com